Method of treating a disease condition caused or exacerbated by an HPV
AssigneeInstitute of Molecular and Cell Biology
InventorsHans-Ulrich Bernard, Yee Joo Tan, Walter Beerheide, Anthony Eugene Ting, Mui Mui Sim
Life of this patent
Estimating the term…
Abstract
The invention provides agents and compounds (see (I) and (II)) for use in the treatment or prophylaxis of disease conditions caused or exacerbated by mammalian papillomaviruses, such as human papillomaviruses, as well as methods for the treatment or prevention thereof. In said formulae, R1–R4 and n are as defined herein.
Claims24
A method of treating a disease condition caused or exacerbated by an HPV wherein said disease condition is cervical cancer or precursor lesions thereof, asymptomatic infections of the cervix and genital, common, plantar or planar warts, comprising the administration to a mammal in need thereof of an effective amount of a compound which facilitates disruption of a chelated metal cation domain of a protein encoded for by an HPV gene, wherein the compound is selected from the group of compounds consisting of formulae (I):
- wherein
- n is selected from 1–5
- R1–R4 are independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted arylalkyl optionally substituted acyl, optionally substituted heterocyclyl, halo alkyl, arylalkyl, carboxy, carboxy ester and carboxamido;
- or
- R1 and R2 together, and/or R3 and R4 together, independently form a group of formula (a):
- (CH2)l—Um—(CH2)n— (a)
- wherein:
- U is CH2, O, NH or S;
- l and n are independently selected from 0 to 6 and m is 0 or 1 when U is CH2 and m is 1 when U is O, NH or S, such that l+m+n is greater than or equal to 2;
- and wherein any one or more (CH2) or NH groups may be further optionally substituted or a pharmaceutically acceptable derivative thereof.
A method of treating a disease condition caused or exacerbated by an HPV and which is cervical cancer or precursor lesions thereof, asymptomatic infections of the cervix and genital, common, plantar or planar warts comprising the administration of an effective amount of a compound capable of facilitating the disruption of a chelated metal cation domain of a protein encoded for by an HPV gene to a mammal in need thereof, wherein said compound is a compound identified as a compound useful in the treatment of a disease or condition caused or exacerbated by an HPV by a method which comprises contacting a protein molecule containing a chelated metal cation domain, encoded by an HPV gene, with an effective amount of said compound for a time and under conditions sufficient to facilitate disruption of the chelated metal cation domain and directly or indirectly determining the amount of chelated metal cation released wherein the amount of chelated metal cation released is indicative of the disruption of the chelated metal cation domain wherein the compound is selected from the group of compounds consisting of formulae (I):
- wherein
- n is selected from 1–5
- R1–R4 are independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted arylalkyl optionally substituted acyl, optionally substituted heterocyclyl, halo alkyl, arylalkyl, carboxy, carboxy ester and carboxamido;
- or
- R1 and R2 together, and/or R3 and R4 together, independently form a group of formula (a):
- (CH2)l—Um—(CH2)n— (a)
- wherein:
- U is CH2, O, NH or S;
- l and n are independently selected from 0 to 6 and m is 0 or 1 when U is CH2 and m is 1 when U is O, NH or S, such that l+m+n is greater than or equal to 2;
- and wherein any one or more (CH2) or NH groups may be further optionally substituted or a pharmaceutically acceptable derivative thereof.
Dependencies are inferred from the claim text.